BLFS Strangle Strategy
BLFS (BioLife Solutions, Inc.), in the Healthcare sector, (Medical - Instruments & Supplies industry), listed on NASDAQ.
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
BLFS (BioLife Solutions, Inc.) trades in the Healthcare sector, specifically Medical - Instruments & Supplies, with a market capitalization of approximately $1.03B, a beta of 1.97 versus the broader market, a 52-week range of 17.86-29.62, average daily share volume of 429K, a public-listing history dating back to 1989, approximately 159 full-time employees. These structural characteristics shape how BLFS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.97 indicates BLFS has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on BLFS?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current BLFS snapshot
As of May 15, 2026, spot at $20.72, ATM IV 69.90%, IV rank 15.50%, expected move 20.04%. The strangle on BLFS below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on BLFS specifically: BLFS IV at 69.90% is on the cheap side of its 1-year range, which favors premium-buying structures like a BLFS strangle, with a market-implied 1-standard-deviation move of approximately 20.04% (roughly $4.15 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated BLFS expiries trade a higher absolute premium for lower per-day decay. Position sizing on BLFS should anchor to the underlying notional of $20.72 per share and to the trader's directional view on BLFS stock.
BLFS strangle setup
The BLFS strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With BLFS near $20.72, the first option leg uses a $21.76 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed BLFS chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 BLFS shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $21.76 | N/A |
| Buy 1 | Put | $19.68 | N/A |
BLFS strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
BLFS strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on BLFS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on BLFS
Strangles on BLFS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the BLFS chain.
BLFS thesis for this strangle
The market-implied 1-standard-deviation range for BLFS extends from approximately $16.57 on the downside to $24.87 on the upside. A BLFS long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current BLFS IV rank near 15.50% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on BLFS at 69.90%. As a Healthcare name, BLFS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to BLFS-specific events.
BLFS strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. BLFS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move BLFS alongside the broader basket even when BLFS-specific fundamentals are unchanged. Always rebuild the position from current BLFS chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on BLFS?
- A strangle on BLFS is the strangle strategy applied to BLFS (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With BLFS stock trading near $20.72, the strikes shown on this page are snapped to the nearest listed BLFS chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are BLFS strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the BLFS strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 69.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a BLFS strangle?
- The breakeven for the BLFS strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current BLFS market-implied 1-standard-deviation expected move is approximately 20.04%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on BLFS?
- Strangles on BLFS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the BLFS chain.
- How does current BLFS implied volatility affect this strangle?
- BLFS ATM IV is at 69.90% with IV rank near 15.50%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.